Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Milsom, I. Lower urinary tract symptoms in women. Curr Opin Urol 2009;19:337-41
   PubMed Web of Science ®Google Scholar
• Fultz NH, Burgio K, Diokno AC, et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003;189:1275-82
   PubMed Web of Science ®Google Scholar
• Freeman RM. Initial management of stress urinary incontinence: pelvic floor muscle training and duloxetine. BJOG 2006;113(Suppl 1):10-16
   PubMedGoogle Scholar
• Glazener CM, Herbison GP, MacArthur C, et al. Randomized controlled trial of conservative management of postnatal urinary and faecal incontinence: six year follow up. BMJ 2005;330-7
   Google Scholar
• Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet Gynecol 2005;105:999-1005
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Appell R, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A. eds. Incontinence, 3rd edn. Paris, France: Health Publications, 2005:809-54
   Google Scholar
• Espey MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998;798:101-8
   PubMed Web of Science ®Google Scholar
• Thor KB, Hisamitsu T, de Groat WC. Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine. Brain Res Dev Brain Res 1990;54:35-42
   PubMedGoogle Scholar
• Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996;118:150-4
   PubMed Web of Science ®Google Scholar
• Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002;187:40-8
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;170:1259-63
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004;111:249-57
   PubMed Web of Science ®Google Scholar
• Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004;93:311-18
   PubMed Web of Science ®Google Scholar
• Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004;104:511-19
   PubMed Web of Science ®Google Scholar
• Ghoniem GM, Schagen Van Leeuwen J, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005;173:1647-53
   PubMed Web of Science ®Google Scholar
• Castro-Diaz D, Palma PC, Bouchard C, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:919-29
   PubMed Web of Science ®Google Scholar
• Boy S, Reitz A, Wirth B, et al. Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur Urol 2006;50(1):119-25
   PubMed Web of Science ®Google Scholar
• Bent AE, Gousse AE, Hendrix SL, et al. Validation of a two-item quantitative questionnaire for the triage of women with urinary incontinence. Obstet Gynecol 2005;106:767-73
   PubMed Web of Science ®Google Scholar
• Bump RC, Voss S, Beardsworth A, et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int 2008;102:214-18
   PubMed Web of Science ®Google Scholar
• Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-9
   PubMedGoogle Scholar
• Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006;125:120-8
   PubMed Web of Science ®Google Scholar
• Donovan JL, Badia X, Corcos J, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris, France: Health Publications, 2002:267-316
   Google Scholar
• Oelke M, Roovers JP, Michel MC. Safety and tolerability of duloxetine in women with stress urinary incontinence. BJOG 2006;113(Suppl 1):22-6
   PubMed Web of Science ®Google Scholar
• Clinical Trial Results web site: http://www.clinicalstudyresults.org/documents/company-study_3154_0.pdf; page 25, accessed Aug 12, 2009
   Google Scholar